WallStreetZenWallStreetZen

NASDAQ: ESPR
Esperion Therapeutics Inc Stock

$2.61-0.07 (-2.61%)
Updated Feb 21, 2024
ESPR Price
$2.61
Fair Value Price
$3.88
Market Cap
$296.80M
52 Week Low
$0.70
52 Week High
$6.75
P/E
-1.11x
P/B
-0.72x
P/S
1.07x
PEG
N/A
Dividend Yield
N/A
Revenue
$102.90M
Earnings
-$208.39M
Gross Margin
65%
Operating Margin
-145.91%
Profit Margin
-202.5%
Debt to Equity
-1.54
Operating Cash Flow
-$141M
Beta
0.96
Next Earnings
Feb 27, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ESPR Overview

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Zen Score

Industry Average (24)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ESPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ESPR ($2.61) is undervalued by 32.69% relative to our estimate of its Fair Value price of $3.88 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ESPR ($2.61) is significantly undervalued by 32.69% relative to our estimate of its Fair Value price of $3.88 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ESPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ESPR due diligence checks available for Premium users.

Be the first to know about important ESPR news, forecast changes, insider trades & much more!

ESPR News

Valuation

ESPR fair value

Fair Value of ESPR stock based on Discounted Cash Flow (DCF)
Price
$2.61
Fair Value
$3.88
Undervalued by
32.69%
ESPR ($2.61) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ESPR ($2.61) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ESPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ESPR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.11x
Industry
6.4x
Market
28.8x

ESPR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-0.72x
Industry
2.24x

ESPR's financial health

Profit margin

Revenue
$34.0M
Net Income
-$41.3M
Profit Margin
-121.4%
ESPR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ESPR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$221.3M
Liabilities
$631.3M
Debt to equity
-1.54
ESPR's short-term assets ($218.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ESPR's long-term liabilities ($493.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ESPR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ESPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$19.3M
Investing
$0.0
Financing
-$4.3M
ESPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ESPR vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
ESPR$296.80M-2.61%-1.11x-0.72x
CGC$313.43M-2.82%-0.21x0.77x
KMDA$269.45M-0.74%42.93x1.13x
LFCR$243.49M0.00%-1.42x7.12x
SIGA$368.97M+2.37%-64.88x2.97x

Esperion Therapeutics Stock FAQ

What is Esperion Therapeutics's quote symbol?

(NASDAQ: ESPR) Esperion Therapeutics trades on the NASDAQ under the ticker symbol ESPR. Esperion Therapeutics stock quotes can also be displayed as NASDAQ: ESPR.

If you're new to stock investing, here's how to buy Esperion Therapeutics stock.

What is the 52 week high and low for Esperion Therapeutics (NASDAQ: ESPR)?

(NASDAQ: ESPR) Esperion Therapeutics's 52-week high was $6.75, and its 52-week low was $0.70. It is currently -61.3% from its 52-week high and 272.86% from its 52-week low.

How much is Esperion Therapeutics stock worth today?

(NASDAQ: ESPR) Esperion Therapeutics currently has 113,717,785 outstanding shares. With Esperion Therapeutics stock trading at $2.61 per share, the total value of Esperion Therapeutics stock (market capitalization) is $296.80M.

Esperion Therapeutics stock was originally listed at a price of $14.50 in Jun 26, 2013. If you had invested in Esperion Therapeutics stock at $14.50, your return over the last 10 years would have been -82%, for an annualized return of -15.76% (not including any dividends or dividend reinvestments).

How much is Esperion Therapeutics's stock price per share?

(NASDAQ: ESPR) Esperion Therapeutics stock price per share is $2.61 today (as of Feb 21, 2024).

What is Esperion Therapeutics's Market Cap?

(NASDAQ: ESPR) Esperion Therapeutics's market cap is $296.80M, as of Feb 22, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Esperion Therapeutics's market cap is calculated by multiplying ESPR's current stock price of $2.61 by ESPR's total outstanding shares of 113,717,785.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.